10-K: STERIS plc Reports Strong Fiscal 2025 Revenue Growth and Significant Debt Reduction Following Dental Segment Divestiture

STERIS plc announced a 6.2% increase in total revenues to $5.46 billion for fiscal year 2025, driven by robust performance in its Healthcare and Applied Sterilization Technologies segments, alongside a substantial reduction in debt after the sale of its Dental business.

Summary

• Total revenues for fiscal year ended March 31, 2025, increased by $320.8 million, or 6.2%, to $5,459.5 million, compared to $5,138.7 million in fiscal 2024, primarily due to higher volume and pricing.
• Gross profit percentage improved to 44.0% in fiscal 2025 from 43.2% in fiscal 2024, benefiting from favorable pricing, mix, productivity, and material costs.
• Income from operations rose 3.7% to $866.6 million in fiscal 2025, up from $836.1 million in fiscal 2024, despite increased legal costs, an EO litigation settlement, higher labor costs, and restructuring expenses.
• Cash flows provided by operating activities increased by 18.0% to $1,148.1 million in fiscal 2025, compared to $973.3 million in fiscal 2024.
• Free cash flow improved to $787.2 million in fiscal 2025 from $620.3 million in fiscal 2024, driven by higher collections on accounts receivable and improved inventory management.
• The debt-to-total capital ratio significantly decreased to 23.6% at March 31, 2025, from 33.7% at March 31, 2024, largely due to debt repayment from the Dental segment divestiture.
• The Dental segment was divested on May 31, 2024, for total cash consideration of $787.5 million, with a potential additional $12.5 million contingent payment.
• A targeted restructuring plan was adopted in May 2024, eliminating approximately 300 positions, with an estimated annual improvement in income from operations of $25.0 million, primarily beginning in fiscal 2026.
• STERIS agreed to pay up to $48.2 million to resolve substantially all personal injury claims related to Ethylene Oxide (EO) exposure pending in the Circuit Court of Cook County, Illinois.

Sentiment

Score: 8

Explanation: The overall sentiment is positive due to strong revenue growth, improved profitability margins, significant cash flow generation, and a substantial reduction in debt. The successful divestiture of the Dental segment and excellent safety performance further contribute to a favorable outlook. While there are increased operating expenses and a notable litigation settlement, the company's core financial health and strategic execution appear robust.

Positives

• Total revenues increased by 6.2% to $5,459.5 million in fiscal 2025, reflecting strong demand and effective pricing strategies.
• Gross profit percentage improved to 44.0% in fiscal 2025, driven by favorable pricing, product mix, productivity gains, and lower material costs.
• Cash flows provided by operating activities increased by 18.0% to $1,148.1 million, and free cash flow increased by 26.9% to $787.2 million, indicating strong cash generation.
• The debt-to-total capital ratio significantly improved to 23.6% from 33.7%, demonstrating enhanced financial leverage and reduced indebtedness.
• The successful divestiture of the Dental segment generated $787.5 million in cash proceeds, which were primarily used to pay down existing debt.
• The company has consistently increased its quarterly dividend since 2005, including an increase to $0.57 per share in fiscal 2025.
• Backlog increased in both the Healthcare segment (to $369.2 million from $353.8 million) and Life Sciences segment (to $83.7 million from $71.4 million), indicating strong future demand.
• STERIS reported zero Class I recalls in fiscal 2025, 2024, or 2023, and no FDA warning letters, seizures, or consent decrees in fiscal 2025, highlighting strong product quality and regulatory compliance.
• Workplace injury prevention results (TRIR of 1.11 and LTIR of 0.38 in fiscal 2025) are within the manufacturing sector's best-in-class performance, demonstrating a commitment to employee safety.
• An 88% employee pulse survey completion rate with strong favorability in engagement, leadership effectiveness, inclusion, belonging, and job experience indicates a positive internal culture.

Negatives

• Capital equipment revenues decreased by 6.0% in fiscal 2025, reflecting declines in both the Healthcare and Life Sciences segments.
• Life Sciences revenues decreased by 5.1% in fiscal 2025, partially due to the divestiture of the CECS business and a 24.4% decline in capital equipment revenues.
• Operating expenses increased by 11.1% in fiscal 2025, primarily driven by increased compensation and benefit costs, legal costs, and the $48.2 million Ethylene Oxide (EO) litigation settlement.
• Restructuring expenses significantly increased by 76.8% to $46.0 million in fiscal 2025, reflecting costs associated with a strategic shift in the European surgical business and other efficiency initiatives.
• The AST segment's operating margins decreased to 44.8% from 46.1%, primarily due to higher labor costs and unfavorable productivity, despite increased pricing and volume.
• The company recorded a pre-tax loss on the sale of the Dental segment of $13.995 million in fiscal 2025, attributed to sale price adjustments related to working capital.

Risks

• Adverse economic cycles or conditions, including customer, regulatory, or government responses, could negatively affect results of operations and increase bad debt losses.
• Ongoing geopolitical instability may cause supply chain disruptions, rising inflation, volatility in capital markets and foreign currency exchange rates, rising interest rates, reduced demand, and heightened cybersecurity risks.
• Changes to international trade policy, such as increased tariffs, could lead to higher production costs, product pricing, supply chain disruptions, limited market access, and lower profitability.
• Changes in healthcare policy or government and other third-party payor reimbursement levels could negatively impact the business, especially if government funding for healthcare becomes limited.
• Failure to receive or maintain, or delays in receiving, regulatory clearance or approval for products and operations may negatively impact revenues, profitability, financial condition, or value.
• Products are subject to recalls and restrictions, even after regulatory clearance, which could divert managerial and financial resources and harm reputation.
• Exposure to product liability claims, other legal actions, or regulatory/compliance matters could result in substantial costs, restrictions on product use or sales, or distract management.
• Difficulties in acquiring or maintaining a proprietary intellectual ownership position, including challenges in obtaining or enforcing patents, or defending against infringement claims, could adversely affect the business.
• Adverse impacts from tax legislation or challenges to tax positions, including changes from the U.S. Tax Cuts and Jobs Act (TCJA), Inflation Reduction Act (IRA) (CAMT), and OECD's BEPS project (GloBE/Pillar Two), could increase tax liabilities or the effective tax rate.
• Changes in tax treaties and trade agreements could negatively impact costs, results of operations, and earnings per share.
• The IRS may assert that STERIS plc should be treated as a U.S. corporation for U.S. federal tax purposes under Section 7874, potentially leading to substantial additional U.S. tax liability and double taxation.
• The highly competitive business environment, including new infection prevention and sterilization products, may exert pressure on pricing strategies or lead to decreasing demand.
• Consolidations among healthcare and pharmaceutical customers may result in a loss of customers or more significant pricing pressures.
• Supply chain disruptions, including volatility in raw material prices (e.g., stainless steel, chemicals, cobalt-60, EO) or reliance on limited suppliers, could increase production costs or curtail operations.
• Business continuity hazards such as explosions, fires, public health crises, extreme weather, utility failures, or labor difficulties could interrupt production or operations.
• Expectations relating to corporate responsibility considerations (e.g., climate change, ESG metrics) expose the company to potential liabilities, increased costs, and reputational harm if goals are not met or reporting is inaccurate.
• Regulations and permitting related to Ethylene Oxide (EO) sterilization, including potential legislative or legal action, could significantly affect costs, impact use, or lead to a shortage of medical devices.
• Litigation related to EO sterilization operations, including mass tort actions, could result in material damages, fines, increased insurance premiums, or diversion of management attention.
• If continuing efforts to create a Lean business and in-source production are not successful, profitability may be negatively impacted.
• A pandemic or similar public health crisis could have a material adverse impact on the ability to staff operations.
• Inability to recruit and retain qualified management and other personnel could impair or disrupt business operations.
• A failure of a key information technology system, process, or a breach of information security, including cybersecurity breaches, could lead to reputational harm, litigation, and regulatory action.
• The company's debt level or access to credit markets may limit financial and business flexibility.
• Inability to successfully identify, price, and integrate strategic business candidates or otherwise optimize the business portfolio could adversely affect growth.
• Business realignment initiatives may not be as successful as anticipated in realizing anticipated benefits or cost savings.
• Integration of acquired businesses may not be as successful as anticipated, leading to operational challenges, failure to realize synergies, or loss of key personnel.
• Acquisitions may not be as accretive to earnings per share and cash flow from operations per share as expected.
• Significant transaction and related costs in connection with business acquisitions and dispositions may be in excess of those anticipated.
• Goodwill and other intangible assets could become impaired, resulting in material non-cash charges to results of operation in the future.

Future Outlook

STERIS expects to manage costs, grow its business through internal product and service development, invest in greater capacity, and augment these methods with potential acquisitions in fiscal 2026 and beyond. The majority of the $25.0 million annual benefit from the restructuring plan is anticipated to begin in fiscal 2026. The global minimum tax rules (GloBE), effective from April 1, 2024, are not expected to have a material impact on the company's consolidated financial statements, and STERIS does not expect to be subject to the Corporate Alternative Minimum Tax (CAMT) regime through 2025.

Management Comments

• "WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe."
• "To STERIS, this means we will make a difference by providing world-class products and services for our Customers, safe and rewarding work for our People, and superior returns for our Shareholders."
• "We are committed to understanding and managing these risks through a consistent approach to risk assessment, monitoring, reporting, and mitigation." (referring to Enterprise Risk Management)
• "People are the key to our success, which is reflected in our two core values of people and teamwork. We are committed to the safety and success of our people."
• "Our ultimate goal is to be an incident-free company. The cornerstone of this initiative is the belief that incidents result from unsafe acts or conditions, both of which are preventable." (referring to Health, Safety & Environment initiatives)
• "We are continuously working towards a goal of achieving a [employee turnover] rate of 10% or less, excluding retirements and reductions in force."
• "We are pleased to report that 88% of our employees completed our pulse survey in fiscal 2025. The pulse survey results are grouped around four key themes: Employee Engagement; Leadership Effectiveness; Inclusion and Belonging; and Job and Work Experience. The results indicate strong favorability in each of these areas."
• "Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized."

Industry Context

STERIS operates in highly competitive and regulated global healthcare, medical device, and pharmaceutical markets. Industry growth is fueled by an aging global population, increased demand for medical procedures (e.g., endoscopies), and customer desires for operational efficiency. The company competes with a diverse range of players, from large global corporations like 3M, Baxter, and Getinge, to smaller specialized firms, across product and service lines including infection prevention, sterile processing, and contract sterilization. Key competitive factors include brand, quality, safety, ease of use, serviceability, price, and technical support. The industry is also influenced by evolving governmental regulations (e.g., FDA, EPA, EU regulations) and healthcare policy changes, particularly regarding reimbursement levels. Consolidation among healthcare and pharmaceutical customers is a notable trend, potentially leading to increased pricing pressures. Furthermore, there's a growing emphasis on corporate responsibility and ESG, with new reporting standards like CSRD impacting industry participants.

Comparison to Industry Standards

• STERIS's annual workplace injury prevention results, with a Total Recordable Incident Rate (TRIR) of 1.11 in fiscal 2025, are better than the manufacturing sector's best-in-class performance of 1.43, as defined by the Bureau of Labor Statistics.
• The company's Lost-time Incident Rate (LTIR) of 0.38 in fiscal 2025 is also better than the manufacturing sector's best-in-class performance of 0.42, as defined by the Bureau of Labor Statistics.
• While the document lists numerous competitors such as 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Karl Storz, Olympus, Ruhof, SteelCo, Stryker, Skytron, Wassenburg, BBraun, Crothall, Pentax, and Sterigenics International, Inc., specific comparative financial or operational metrics against these companies are not provided within the filing to assess performance relative to industry peers beyond safety metrics.

Management Changes

Corporate Governance

Legal Proceedings

• A subsidiary is facing personal injury lawsuits in Illinois state court related to alleged Ethylene Oxide (EO) emissions from a facility in Lake County, Illinois, between 2005 and 2008.
• On March 3, 2025, STERIS entered into binding confidential term sheets and settlement agreements to resolve substantially all of these Illinois EO litigation claims, agreeing to pay up to $48.150 million.
• The company is contesting two Notices of Deficiency from the U.S. Internal Revenue Service (IRS) regarding previously disclosed deemed dividend inclusions and associated withholding tax for fiscal and calendar year 2018, totaling approximately $50.0 million, and has filed petitions with the U.S. Tax Court.

Stakeholder Impact

• **Shareholders**: Positively impacted by strong revenue growth, improved profitability, robust cash flow, and significant debt reduction. The increased quarterly dividend also provides direct returns. However, increased operating expenses, the EO litigation settlement, and restructuring costs represent financial outflows. Ongoing risks from tax law changes and geopolitical instability could affect future returns.
• **Employees**: Positively impacted by the company's commitment to safety, competitive compensation and benefits, and career development programs. Negatively impacted by the elimination of approximately 300 positions due to the restructuring plan. The company aims to reduce employee turnover to 10% or less.
• **Customers**: Benefit from STERIS's innovative healthcare and life science products and services, with a focus on infection prevention and continuous improvement. Potential negative impacts could arise from supply chain disruptions affecting product availability or pricing, or reduced demand due to broader economic downturns or changes in healthcare reimbursement policies.
• **Suppliers**: Face potential impacts from supply chain disruptions, volatility in raw material prices, and changes in international trade policy, which could affect costs and demand for their goods and services.
• **Creditors**: Positively impacted by the significant debt reduction and improved debt-to-total capital ratio, which indicates a stronger financial position and reduced credit risk for outstanding obligations.

Next Steps

• Manage costs effectively in fiscal 2026 and beyond.
• Continue to grow the business through internal product and service development.
• Invest in greater capacity across segments.
• Augment value creation with potential strategic acquisitions of additional products and services.
• Continue efforts to prepare for upcoming Corporate Sustainability Reporting Directive (CSRD) disclosure requirements, including gathering baseline information, strengthening internal controls, and evaluating ESG data.
• Evaluate how TCFD-aligned climate scenario analysis information will inform global reporting requirements.
• Continue to defend against Ethylene Oxide (EO) litigation if walkaway rights are exercised, following the recent settlement process for pending Illinois cases.
• Realize the estimated $25.0 million annual benefit from the targeted restructuring plan, with the majority expected to begin in fiscal 2026.

Key Dates

Recommendation

Keywords

Healthcare, Infection Prevention, Sterilization, Medical Devices, Pharmaceuticals, Life Sciences, Contract Sterilization, Surgical Equipment, Endoscopy, Financial Results, SEC Filing, 10-K, Corporate Governance, Risk Management, Acquisitions, Divestitures, Ethylene Oxide, ESG, Supply Chain, Cybersecurity